[1] Landgren O, Kyle RA, Pfeiffer RM, et al.Monoclonal gammopathy of undetermined significance(MGUS) consistently precedes multiple myeloma: a prospective study[J]. Blood,2009,113(22):5412-5417.
[2] Weiss BM, Abadie J, Verma P, et al.A monoclonal gammopathy precedes multiple myeloma in most patients[J]. Blood,2009,113(22):5418-5422.
[3] Kyle RA, Durie BG, Rajkumar SV, et al.Monoclonal gammopathy of undetermined significance (MGUS) and smoldering (asymptomatic) multiple myeloma: IMWG consensus perspectives risk factors for progression and guidelines for monitoring and management[J]. Leukemia,2010,24(6):1121-1127.
[4] Dispenzieri A, Kyle R, Merlini G, et al.International Myeloma Working Group guidelines for serum-free light chain analysis in multiple myeloma and related disorders[J]. Leukemia,2009,23(2):215-224.
[5] Fonseca R, Bergsagel PL, Drach J, et al.International Myeloma Working Group molecular classification of multiple myeloma: spotlight review[J]. Leukemia,2009, 23(12):2210-2221.
[6] Harousseau JL, Dreyling M, ESMO Guidelines Working Group. Multiple myeloma: ESMO clinical recommendations for diagnosis, treatment and follow-up[J]. Ann Oncol,2009,20(Suppl 4):97-99.
[7] Landgren O.Monoclonal gammopathy of undetermined significance and smoldering myeloma: new insights into pathophysiology and epidemiology[J]. Hematology Am Soc Hematol Educ Program,2010,2010:295-302.
[8] Katzmann JA.Screening panels for monoclonal gammopathies: time to change[J]. Clin Biochem Rev,2009, 30(3):105-111.
[9] Kristinsson SY, Björkholm M, Andersson TM, et al.Patterns of survival and causes of death following a diagnosis of monoclonal gammopathy of undetermined significance: a population-based study[J]. Haematologica,2009, 94(12):1714-1720.
[10] Katzmann JA, Kyle RA, Benson J, et al.Screening pane-ls for detection of monoclonal gammopathies[J]. Clin Chem,2009,55(8):1517-1522.
[11] Kyle RA, Rajkumar SV.Criteria for diagnosis, staging, risk stratification and response assessment of multiple myeloma[J]. Leukemia,2009,23(1):3-9.
[12] Durie BG, Salmon SE.A clinical staging system for multiple myeloma. Correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival[J]. Cancer, 1975, 36(3): 842-854.
[13] Landgren O, Gridley G, Turesson I, et al.Risk of monoclonal gammopathy of undetermined significance (MGUS) and subsequent multiple myeloma among African American and white veterans in the United States[J]. Blood,2006,107(3):904-906.
[14] Iwanaga M, Tagawa M, Tsukasaki K, et al.Prevalence of monoclonal gammopathy of undetermined significance: study of 52,802 persons in Nagasaki City, Japan[J]. Mayo Clin Proc,2007,82(12):1474-1479.
[15] Kyle RA, Rajkumar SV.Management of monoclonal gammopathy of undetermined significance (MGUS) and smoldering multiple myeloma(SMM)[J]. Oncology (Williston Park),2011,25(7):578-586.
[16] Hillengass J, Moehler T, Hundemer M.Monoclonal gammopathy and smoldering multiple myeloma: diagnosis, staging, prognosis, management[J]. Recent Results Cancer Res,2011,183:113-131.
[17] Pérez-Persona E, Vidriales MB, Mateo G, et al.New criteria to identify risk of progression in monoclonal gammopathy of uncertain significance and smoldering multiple myeloma based on multiparameter flow cytometry analysis of bone marrow plasma cells[J]. Blood,2007,110(7):2586-2592.
[18] Kyle RA, Durie BG, Rajkumar SV, et al.Monoclonal gammopathy of undetermined significance(MGUS) and smoldering (asymptomatic) multiple myeloma: IMWG consensus perspectives risk factors for progression and guidelines for monitoring and management[J]. Leukemia,2010,24(6):1121-1127.
[19] Kyle RA, Remstein ED, Therneau TM, et al.Clinical course and prognosis of smoldering (asymptomatic) multiple myeloma[J]. N Engl J Med,2007,356(25):2582-2590.
[20] Greipp PR, San Miguel J, Durie BG, et al.International staging system for multiple myeloma[J]. J Clin Oncol,2005,23(15):3412-3420.
[21] Fonseca R, Bergsagel PL, Drach J, et al.International Myeloma Working Group molecular classification of multiple myeloma: spotlight review[J]. Leukemia,2009, 23(12):2210-2221.
[22] Bradwell AR, Carr-Smith HD, Mead GP, et al.Serum test for assessment of patients with Bence Jones myeloma[J]. Lancet,2003,361(9356):489-491.
[23] Dingli D, Kyle RA, Rajkumar SV, et al.Immunoglobulin free light chains and solitary plasmacytoma of bone[J]. Blood,2006,108(6):1979-1983.
[24] Durie BG, Harousseau JL, Miguel JS, et al.International uniform response criteria for multiple myeloma[J]. Leukemia,2006,20(9):1467-1473.
[25] Palumbo A, Avet-Loiseau H, Oliva S, et al.Revised International Staging System for Multiple Myeloma: A Report From International Myeloma Working Group[J]. J Clin Oncol,2015,33(26):2863-2869.
[26] Fonseca R, Bergsagel PL, Drach J, et al.International Myeloma Working Group molecular classification of multiple myeloma: spotlight review[J]. Leukemia,2009, 23(12):2210-2221.
[27] Keats JJ, Reiman T, Maxwell CA, et al.In multiple myeloma, t(4;14)(p16;q32) is an adverse prognostic factor irrespective of FGFR3 expression[J]. Blood,2003,101(4):1520-1529.
[28] Merz M, Hielscher T, Seckinger A, et al.Baseline characteristics, chromosomal alterations, and treatment affec-ting prognosis of deletion 17p in newly diagnosed myeloma[J]. Am J Hematol,2016,91(11):E473-E477.
[29] Fonseca R, Monge J, Dimopoulos MA.Staging and prognostication of multiple myeloma[J]. Expert Rev Hematol,2014,7(1):21-31.
[30] Chng WJ, Price-Troska T, Gonzalez-Paz N, et al.Clinical significance of TP53 mutation in myeloma[J]. Leukemia,2007,21(3):582-584.
[31] Stewart AK, Bergsagel PL, Greipp PR, et al.A practical guide to defining high-risk myeloma for clinical trials, patient counseling and choice of therapy[J]. Leukemia,2007,21(3):529-534.
[32] Weinhold N, Kirn D, Seckinger A, et al.Concomitant gain of 1q21 and MYC translocation define a poor prognostic subgroup of hyperdiploid multiple myeloma[J]. Haematologica,2016,101(3):e116-e119.
[33] Palumbo A, Bringhen S, Mateos MV, et al.Geriatric assessment predicts survival and toxicities in elderly myeloma patients: an International Myeloma Working Group report[J]. Blood,2015,125(13):2068-2074.
[34] Dispenzieri A, Rajkumar SV, Gertz MA, et al.Treatment of newly diagnosed multiple myeloma based on Mayo Stratification of Myeloma and Risk-adapted Therapy (mSMART): consensus statement[J]. Mayo Clin Proc,2007, 82(3):323-341.
[35] Kumar SK, Mikhael JR, Buadi FK, et al.Management of newly diagnosed symptomatic multiple myeloma: updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus guidelines[J]. Mayo Clin Proc,2009,84(12):1095-1110.
[36] Ria R, Roccaro AM, Merchionne F, et al.Vascular endothelial growth factor and its receptors in multiple myeloma[J]. Leukemia,2003,17(10):1961-1966.
[37] Moreau P, Attal M, Garban F, et al.Heterogeneity of t(4;14) in multiple myeloma. Long-term follow-up of 100 cases treated with tandem transplantation in IFM99 trials[J]. Leukemia,2007,21(9):2020-2024.
[38] Fonseca R, Bergsagel PL, Drach J, et al.International Myeloma Working Group molecular classification of multiple myeloma: spotlight review[J]. Leukemia,2009, 23(12):2210-2221.
[39] Zhou Y, Barlogie B, Shaughnessy JD Jr.The molecular characterization and clinical management of multiple myeloma in the post-genome era[J]. Leukemia,2009,23(11):1941-1956.
[40] Decaux O, Lodé L, Magrangeas F, et al.Prediction of survival in multiple myeloma based on gene expression profiles reveals cell cycle and chromosomal instability signatures in high-risk patients and hyperdiploid signatures in low-risk patients: a study of the Intergroupe Francophone du Myélome[J]. J Clin Oncol,2008,26(29):4798-4805.
[41] Shaughnessy JD Jr, Zhan F, Burington BE, et al.A validated gene expression model of high-risk multiple myeloma is defined by deregulated expression of genes mapping to chromosome 1[J]. Blood,2007,109(6):2276-2284.
[42] Kuiper R, Broyl A, de Knegt Y, et al. A gene expression signature for high-risk multiple myeloma[J]. Leukemia,2012,26(11):2406-2413.
[43] Sun RX, Lu ZY, Wijdenes J, et al.Large scale and clinical grade purification of syndecan-1+ malignant plasma cells[J]. J Immunol Methods,1997,205(1):73-79.
[44] Rawstron AC, Orfao A, Beksac M, el al. Report of the European Myeloma Network on multiparametric flow cytometry in multiple myeloma and related disorders[J]. Haematologica,2008,93(3):431-438.
[45] Flanders A, Stetler-Stevenson M, Landgren O.Minimal residual disease testing in multiple myeloma by flow cytometry: major heterogeneity[J]. Blood,2013,122(6):1088-1089.
